Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft.
Based on previous work demonstrating the activity of cyclophosphamide and melphalan in a series of human medulloblastoma and rhabdomyosarcoma cell lines and transplantable xenografts, investigations were conducted to define the effects of combining cyclophosphamide or melphalan with VP-16. These studies demonstrated a synergistic interaction between cyclophosphamide and VP-16 and melphalan and VP-16 in the treatment of the human rhabdomyosarcoma cell line TE-671 growing in athymic mice. The combination of cyclophosphamide or melphalan with VP-16 may warrant consideration as a therapeutic strategy for solid tumors sensitive to bifunctional alkylating agents.
Lilley
E R
ER
Department of Pediatrics, Duke University Medical Center, Durham, NC 27710.
Rosenberg
M C
MC
Elion
G B
GB
Colvin
O M
OM
Bigner
D D
DD
Friedman
H S
HS
D000477:Alkylating Agents / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000494:pharmacology*; D004273:DNA, Neoplasm / Q000187:drug effects; D004357:Drug Synergism; D005047:Etoposide / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D008297:Male; D008558:Melphalan / Q000008:administration & dosage / Q000494:pharmacology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D012208:Rhabdomyosarcoma / Q000188:drug therapy*; D014183:Transplantation, Heterologous
D000477:Alkylating Agents; D004273:DNA, Neoplasm; D005047:Etoposide; D003520:Cyclophosphamide; D008558:Melphalan